Recently, the 2025 Deloitte China Technology Fast Program Award Ceremony was successfully held in Wuxi, China. After a three-month selection process, Dermavon, the skin health business company of CMS, was included in the list of “Deloitte China LSHC Rising Star” by virtue of its leading innovative product layout in the skin health field, as well as its promising growth and development potential. The theme of this year’s “Technology Fast Program” selection is “Boundless Innovation, Resilient Growth”. Through the review by the Professional Committee, enterprise presentation and scoring, and other processes, the selection comprehensively evaluates enterprise valuation, technological innovation, market prospects, industry ranking, etc., and selects excellent enterprises with both innovation capabilities and growth potential, so as to encourage enterprises to break through technological boundaries and promote the continuous construction of the innovation ecosystem. Being selected into this list is a full recognition of Dermavon’s leading industry position, comprehensive and differentiated innovative product portfolio, […]
Learn More
Povorcitinib is a selective oral small molecule JAK1 inhibitor undergoing clinical development in China. It has been included in the list of Breakthrough Therapeutic Drugsby CDE of China’s NMPA with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product. China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National […]
Learn More
Recently, CMS has been successfully selected as a constituent stock of the Hong Kong Exchanges and Clearing Tech 100 Index (“HKEX Tech 100”). As the first Hong Kong stock index launched by HKEX, it aims to track the performance of the 100 largest-cap Hong Kong-listed companies that are highly relevant to the technology theme and eligible for the Southbound Stock Connect, covering six cutting-edge sectors including artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and intelligent driving. Its launch responds to the diversified investment demands of the capital market for the technology sector, providing investors with an efficient tool to allocate assets in leading Hong Kong-listed technology companies. This inclusion fully reflects the capital market’s recognition of CMS’s innovative development strength and investment prospects. CMS is firmly advancing its three core strategies of product innovation, commercial model reform and international expansion, and is gradually achieving the strategic transition to a “specialty-focused, innovation-excellent international […]
Learn MoreThe news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.
